Haemonetics Corp. (NYSE:HAE)’s share price traded down 2.3% during trading on Friday . The stock traded as low as $29.76 and last traded at $29.76, with a volume of 186,287 shares changing hands. The stock had previously closed at $30.46.

Several equities analysts have commented on the stock. Morgan Stanley reissued a “hold” rating on shares of Haemonetics Corp. in a report on Tuesday, May 3rd. BTIG Research reaffirmed a “hold” rating on shares of Haemonetics Corp. in a report on Tuesday, April 19th. Barrington Research decreased their price target on shares of Haemonetics Corp. from $40.00 to $32.00 and set an “outperform” rating on the stock in a report on Tuesday, May 3rd. Goldman Sachs Group Inc. raised shares of Haemonetics Corp. from a “sell” rating to a “neutral” rating and set a $29.00 price target on the stock in a report on Monday, May 16th. Finally, Benchmark Co. decreased their price target on shares of Haemonetics Corp. from $35.00 to $28.00 and set a “hold” rating on the stock in a report on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. Haemonetics Corp. has an average rating of “Hold” and an average price target of $32.25.

The firm’s market cap is $1.53 billion. The firm has a 50 day moving average price of $29.31 and a 200-day moving average price of $31.20.

Haemonetics Corp. (NYSE:HAE) last announced its quarterly earnings results on Monday, May 2nd. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by $0.09. The firm had revenue of $243.20 million for the quarter, compared to analysts’ expectations of $245.08 million. During the same quarter last year, the firm posted $0.47 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. On average, equities research analysts predict that Haemonetics Corp. will post $1.45 earnings per share for the current fiscal year.

Other large investors recently made changes to their positions in the company. Comerica Bank increased its stake in shares of Haemonetics Corp. by 0.6% in the fourth quarter. Comerica Bank now owns 52,596 shares of the company’s stock worth $1,596,000 after buying an additional 321 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Haemonetics Corp. by 3.0% in the fourth quarter. New York State Common Retirement Fund now owns 55,769 shares of the company’s stock worth $1,798,000 after buying an additional 1,600 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Haemonetics Corp. by 1.3% in the fourth quarter. Rhumbline Advisers now owns 75,509 shares of the company’s stock worth $2,434,000 after buying an additional 935 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Haemonetics Corp. by 30.3% in the fourth quarter. Nationwide Fund Advisors now owns 91,267 shares of the company’s stock worth $2,942,000 after buying an additional 21,233 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Haemonetics Corp. by 1.5% in the fourth quarter. California State Teachers Retirement System now owns 95,732 shares of the company’s stock worth $3,086,000 after buying an additional 1,440 shares in the last quarter.

Haemonetics Corporation is a healthcare company, which provides blood management solutions to its customers. The Company’s portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.